Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-22
DOI
10.3389/fmolb.2022.834841
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
- (2021) Tan-Trieu Nguyen et al. CLINICAL CANCER RESEARCH
- Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
- (2021) Johannes Kleemann et al. Cancer Management and Research
- Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
- (2021) Varun Monga et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
- (2021) Megumi Kai et al. Scientific Reports
- Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database
- (2020) Karly S Louie et al. Future Oncology
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
- (2020) Ciara M. Kelly et al. JAMA Oncology
- Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
- (2020) Kevin J Harrington et al. CLINICAL CANCER RESEARCH
- SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer
- (2020) Tomas Pascual et al. Future Oncology
- A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
- (2020) Alexander C. J. van Akkooi et al. ADVANCES IN THERAPY
- A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer
- (2020) Hatem Soliman et al. CLINICAL CANCER RESEARCH
- Talimogene laherparepvec (T‐ VEC ) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
- (2019) J. Ressler et al. BRITISH JOURNAL OF DERMATOLOGY
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
- (2019) Praveen K. Bommareddy et al. OncoImmunology
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- (2019) Jason Chesney et al. BRITISH JOURNAL OF CANCER
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Oncorine, the World First Oncolytic Virus Medicine and its Update in China
- (2018) Min Liang CURRENT CANCER DRUG TARGETS
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- The advent of oncolytic virotherapy in oncology: The Rigvir® story
- (2018) Pēteris Alberts et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
- (2018) Peter Mohr et al. ADVANCES IN THERAPY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
- (2017) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
- (2017) Gustavo Schvartsman et al. Journal for ImmunoTherapy of Cancer
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment
- (2016) Petra Kucerova et al. ANTI-CANCER DRUGS
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now